![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 12, 2008 1:21:05 PM
Novartis held the antifungal back and didn't submit a NDA to the FDA for some unstated reason. That's the day the stock fell tremendously. Since then we got news of a patent and a 3.5 mil milestone payment for the drug.
So looking at the CC, we hear the following.
---------------------------------------------------------------
For antifungal product that's licensed to Novartis, we announced in October that we received a notice of allowance on our U.S. patent application for the product and trigger the long awaited $3.5 million from Novartis. This patent when issued provides Novartis important protection on the commercial product. In light of the significant delay in the review and approval of our product, the U.S. Patent Office added 756 days to the life of the patent coverage for protection that's now out to April of 2026.
Novartis recently completed their analysis of two Phase III studies. They have agreed that they would share the data with us with the provision that for competitive reasons we cannot share the data with anyone outside of the company. Contractually, the data is theirs, so we have to abide by their wishes. In the meantime, they have assured us that they will complete patient testing and ongoing Phase III comparative study in Europe, which is scheduled to conclude in early 2009. They are also very actively exploring various options for the U.S. and we will keep you updated as we progress with Novartis.
---------------------------------------------------------------
Key Points:
- Novartis holds the NM100060 and doesn't submit NDA to FDA
- NEXMED receives [LATE] patent for NM100060
- NEXMED states in CC that patent provides Novartis important protection on the commercial product.
- NEXMED states in CC they can't share data from Phase III of Novartis studies
- NEXMED states in CC Novartis continues ongoing comparative study in Europe for Phase III
Reading between the lines of what was said, I can make a lot of assumptions. Novartis possibly was holding back NDA because of no patent. Novartis is waiting on Phase III studies in Europe before submitting to FDA in U.S. Here's a key point though, Novartis continues COMPARATIVE studies in Europe, meaning that there is the probability that those Phase III studies in the U.S. were a success. We don't know because that data is held back from the public, but the studies continue in Europe so obviously something must have gone right.
Recent SEEL News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:05:35 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/31/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:01:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 01:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 03:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:00:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM